Bayerische Motoren Werke ADR (BMWYY)

NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a letter from the FDA’s Bioequivalence Program stating no bioequivalence deficiencies were identified at this time in its Abbreviated New Drug Application, with a preliminary determination ahead of anticipated approval in Summer 2026. The company highlighted its preservative-free ketamine formulation, which excludes benzethonium chloride, as a potential advancement in safety and stability, while continuing to pursue regulatory pathways for broader therapeutic use.

We, Foshan Tiancai Aluminum Co. Ltd., participated in The 16th Zhengzhou International Automobile Exhibition (ZZIAE) , held from June 26th to June 28th, 2025 . Our booth was located at 2C371 2C365 . During this exhibition, we showcased our newly developed products. We welcome you to visit our booth and explore the innovative solutions we have on display.

Most existing cancer treatments not only attack cancer cells but also adversely impact healthy body cells. The resultant damage to healthy tissues usually triggers side effects that often become severe, necessitating discontinuation of therapy or making quality of life worse. Scientists have been looking for better treatments that only impact malignant cells and leave healthy cells unaffected. A new preclinical study documents one such discovery leveraging the use of a mirror-image molecule.

OXNARD, CA - March 16, 2026 - PRESSADVANTAGE - Prestige Bodyworks, a leading collision repair facility in Oxnard, California, continues to advance industry standards through its comprehensive approach to vehicle...

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined, have the potential to improve outcomes and results for cancer patients.

Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent years. However, not all malignancies respond to these therapies, and those that do often become resistant, or are discontinued due to adverse reactions within the immune system. Now, researchers have shown that gut microbiota are one of the key factors influencing the success of immunotherapy targeting PD-L1 and PD-1 gene expression.

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, announced the acquisition of Ignite Proteomics LLC, a commercial-stage precision oncology company focused on improving therapy selection in cancer care through functional proteomics. Ignite’s Reverse Phase Protein Array platform is designed to measure protein expression and activity directly from tumor samples, providing insight into whether targeted therapies are likely to be effective, information that may not be captured by genomic testing alone. Under the terms of the transaction, Aditxt acquired Ignite through the issuance of 36,000 shares of newly designated Series A-2 Convertible Preferred Stock with an aggregate stated value of $36 million, with Ignite to operate as a subsidiary within Aditxt’s oncology initiatives.

As of March 12, 2026, the global aluminum market is navigating a period of intense volatility and structural shifts, with prices on the London Metal Exchange (LME) surging to nearly four-year highs between $3,269 and $3,544 per tonne. While the industry entered the year with cautious optimism, a

California, led by Democratic governor Gavin Newsom, has decided to break with the federal positions on public health and has resolved to stand by policies backed by science rather than the controversial positions being taken by the federal government through its health secretary R. F. Kennedy Jr.

The global trade landscape was thrown into a state of high-stakes volatility this quarter as President Trump issued a stark ultimatum to America’s closest European allies: enter negotiations for the sale of Greenland or face a devastating "Greenland Surcharge" on all exports to the United States. The proposal, which

Voyager Acquisition (NASDAQ: “VACHU,” “VACH,” “VACHW”) announced that holders of 25,217,315 Class A ordinary shares — representing approximately 99.67% of the shares outstanding — exercised their redemption rights in connection with the company’s planned business combination with VERAXA Biotech AG. Following the redemptions, approximately $885,556 will remain in Voyager’s trust account and 82,685 Class A shares will convert into shares of VERAXA Biotech Holding AG, with the combined company expected to trade on Nasdaq under the ticker “VRXA” upon completion of the transaction.

Earth Science Tech (OTC: ETST), a strategic holding company, operates a portfolio in the pharmaceutical, telemedicine, healthcare and consumer markets. The company strives to build value by acquiring and actively managing businesses and focuses on controlling interests in companies where regulatory compliance, operational oversight, and disciplined scaling can drive growth.

Oragenics (NYSE American: OGEN) announced it is exploring potential acquisitions of additional central nervous system assets focused on brain health and brain recovery indications that align with its proprietary intranasal drug delivery platform and lead candidate ONP-002. The company said the initiative complements its existing AI-enabled drug discovery collaboration with Receptor.AI and is intended to build a diversified CNS pipeline, while ONP-002 continues advancing through Phase IIa clinical trials in Australia targeting concussion and mild traumatic brain injury with plans for U.S. Phase IIb studies following a future IND submission.

Monticello, AR - March 10, 2026 - Strokers Diesel Performance & Repair delivers dealer-level diagnostics and specialist expertise for all vehicle categories throughout Monticello and Southeast Arkansas. The shop is widely recognized for solving complex heavy-duty diesel problems on Cummins, Duramax, and Powerstroke engines, but the same premium equipment and diagnostic precision serve Honda, Toyota, Audi, BMW, Volkswagen, and everyday passenger vehicles.

Date: March 10, 2026 Introduction As of early 2026, Tesla Inc. (NASDAQ: TSLA) stands at a defining crossroads that will determine the trajectory of the automotive and tech industries for the next decade. No longer viewed strictly as a car company by its most ardent supporters—nor dismissed as a mere "meme stock" by its harshest [...]

South Korean scientists have published the results of a study that provides vital insights indicating that brain cancer develops much earlier than the time when tumors become visible. Their findings could alter how brain cancer treatment is approached, especially efforts geared at limiting the possibility of its recurrence.

Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy.

For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the European Medicines Agency (EMA) not only validates a drug’s scientific rationale but can also unlock development incentives that accelerate its path forward. In that context, Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing treatments for rare diseases and areas of unmet medical need, announced that it has received a positive opinion from the EMA’s Committee for Orphan Medicinal Products for its pipeline product dusquetide in the treatment of Behcet’s disease.

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its positioning opposite of many capitalization structures in the landscape of over-the-counter (“OTC”) markets, with its management team owning over 47% of the company’s shares. “This high level of insider ownership is significant, as it shows the leadership team strongly believes in the company and has financial outcomes tied closely to the stock’s performance,” reads the publication. “As a result, this greatly reduces the risk that management benefits while investors don’t, as management is financially aligned with outside investors… This high insider ownership also ensures the company is intensely focused on creating shareholder value, as even a tiny swing in the stock price could have massive financial implications for the team… and also points to the company funding operations through cash flow, and not toxic financing.”

As of March 6, 2026, Tesla Inc. (NASDAQ: TSLA) finds itself at a historical crossroads. Once the undisputed vanguard of the global electric vehicle (EV) revolution, the Austin-headquartered titan is currently navigating a complex "identity transition." The company is shifting its strategic weight from a pure-play automotive manufacturer toward a multifaceted powerhouse of "Physical AI" [...]

Oregon State University researchers have engineered a new nanomaterial from iron that kills cancer cells inside tumors and leaves normal cells unaffected. This new nanomaterial works by triggering two chemical reactions inside tumors and the cancer cells die off as a result of these reactions.

Ituran (ITRN) Q4 2025 Earnings Call Transcript

As of March 5, 2026, Nio Inc. (NYSE: NIO; HKEX: 9866) stands at a historic crossroads. Long criticized by skeptics for its "cash-burning" philosophy and niche premium positioning, the Shanghai-headquartered automaker has spent the last year engineering one of the most significant pivots in the global electric vehicle (EV) sector. Today, Nio is no longer [...]

Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication, companies are developing platform technologies that allow a single therapeutic approach to be adapted across conditions. Soligenix (NASDAQ: SNGX) exemplifies this strategy through its use of synthetic hypericin across two distinct dermatologic indications, illustrating how platform science can streamline development and expand clinical impact.